Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
about
Natural Killer Cells for Therapy of LeukemiaNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Cord Blood as a Source of Natural Killer CellsNatural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityThe Application of Natural Killer Cell Immunotherapy for the Treatment of CancerAlloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive ImmunotherapyImmune Modulation in Hematologic MalignanciesT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectThe role of regulatory T cells in cancer immunologyFunctional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell TransplantationManufacturing Natural Killer Cells as Medicinal ProductsImproving natural killer cell cancer immunotherapyNatural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation.Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentratesNatural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspectiveThe Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.Haematological malignancies: at the forefront of immunotherapeutic innovation.Natural killer cell therapy in children with relapsed leukemia.Challenges and opportunities of allogeneic donor-derived CAR T cellsEzh2 regulates differentiation and function of natural killer cells through histone methyltransferase activityElevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses.Repression of GSK3 restores NK cell cytotoxicity in AML patients.UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.New approaches for the immunotherapy of acute myeloid leukemia.The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.Natural Killer Cell Immunotherapy: From Bench to BedsideNatural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.NK cell-based cancer immunotherapy: from basic biology to clinical application.Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular TherapiesChimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.
P2860
Q26745906-5CF31B7D-05DC-4B1D-832F-5FF9D5D0FC31Q26770391-A2372246-7D33-442A-806C-47DFE51DAE11Q26771337-56983A7D-2806-49D9-AB95-D5D1F3C9C095Q26773135-FE7C6B16-4F78-43A4-9A67-2BD4D044F0C4Q26774678-1D866B89-17D4-4E92-8D35-CD0E05CA5EBFQ26777209-0530A51F-D5AB-41CD-B4CE-1784F1752297Q26796307-6D13DD1E-F158-484F-9178-7605CE7B702AQ26826830-E11AD86D-7CEB-4AB3-8075-469B960C6AF8Q27006663-2E49613A-72A2-496D-A937-1CAC2D816E7AQ28069682-8FDD77D2-843C-42D4-BE73-6F129C05B1BDQ28069992-FBA60756-5B37-491A-B02D-28EF964BFD3BQ28087719-541E23BB-CEC5-43CC-B69B-AF3E801DAF7AQ33600093-D3A6763C-E1FD-4C52-8AA0-7B07D09A805CQ33703046-ECAB6CEE-FFD8-4B66-93AE-D91E60204FD0Q33922539-97145600-3B83-4E7A-9C76-AAB927CC6F86Q34180695-71B5D380-9C71-477B-A586-63ADBD7E235EQ34553267-D697435B-D866-459E-897C-9A99C044EE51Q35029441-5FD0DA3F-2948-44E1-AC59-253152AF4D84Q35600095-F9089958-AA46-455F-9445-A8B90BF98842Q35711209-871285B2-EA69-4D56-B756-362B0DBFED2AQ35880618-50B46BF9-D422-46AD-A545-2E67C266AD70Q36251948-4C2C2CB3-55A3-463B-A7A6-89F6ED4A750FQ36257036-EF048094-9F53-4432-A28A-5C804E8FABD1Q36435156-763717B5-B5CE-4689-9CEA-742594D430E6Q36467544-6293762C-A4BB-4B66-9EFC-08CCFA76377CQ36712059-6C05B5AE-06DC-40A5-A9C2-AD194A68D008Q36745048-E04A7B12-AF3A-498A-9E0D-CA0DD05AA198Q36768725-13414453-7A5C-40C1-880C-59BC2AC8C558Q36966726-B58F58B1-C6C2-4FD4-9FCB-04AC7F2783FAQ37058110-14A63E55-B930-468A-8931-211982226A2AQ37517482-ED51C2DA-17FE-4D6F-BB03-768A4673FF67Q37624593-BBDF591D-D9F6-4C7E-87A7-35E0FF3A87C4Q38482206-5F24D946-67F7-4654-BB88-F0BC40A07B4FQ38513534-B5C58758-5CB9-4A89-8CEB-3EC542E478CEQ38531958-7C3BE0A4-7A2B-4883-8F7B-E53C6972F32FQ38599353-A8EBFE6A-6F2B-418B-B291-48928E9B01BAQ38640489-8AB21323-BB4A-464B-987D-E350EAD8B291Q38643300-D508C957-8097-4DB3-807B-86536249599DQ38651290-0751FA43-7DFC-43F0-91B5-7CDE2F53C1DDQ38666579-2000AD7D-7BC1-4475-A5AF-818A08BD4D6F
P2860
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Clearance of acute myeloid leu ...... phtheria toxin fusion protein.
@ast
Clearance of acute myeloid leu ...... phtheria toxin fusion protein.
@en
type
label
Clearance of acute myeloid leu ...... phtheria toxin fusion protein.
@ast
Clearance of acute myeloid leu ...... phtheria toxin fusion protein.
@en
prefLabel
Clearance of acute myeloid leu ...... phtheria toxin fusion protein.
@ast
Clearance of acute myeloid leu ...... phtheria toxin fusion protein.
@en
P2093
P2860
P1433
P1476
Clearance of acute myeloid leu ...... phtheria toxin fusion protein.
@en
P2093
Daniel J Weisdorf
David H McKenna
Dixie Lewis
Jeffrey S Miller
Julie Curtsinger
Keli Hippen
Michael R Verneris
Philip McGlave
Sarah Cooley
P2860
P304
P356
10.1182/BLOOD-2013-10-532531
P407
P577
2014-04-09T00:00:00Z